Newsgroup: it.salute
Titolo: Calvizie

Ragazzi c' e' qualcuno di voi che ha fermato o sa come fermare l'
avanzare apparentemente ineluttabile della calvizie? Lungi da me
centri tricologici e menate varie, intendo mix di medicinali seri
sotto supervisione del dermatologo. Sapete com' e' il mio non conosce
bene tutti i prodotti :-)
Grazie a chi rispondera'.

avanzare apparentemente ineluttabile della calvizie?
Nessuno puň fermarla. Non esistono farmaci in grado di risolvere il
problema. Se vuoi esistono dei palliativi (Minoxidil e Finasteride)
ma, una volta sospesi, si ricominciano a perdere capelli.
** Rimuovi uno TSUBO per rispondere **

 
Sbagli Tsubo, l'unica cosa che ferma la caduta dei capelli è il pavimento!!!
Bye bye
Fabio

Sbagli Tsubo, l'unica cosa che ferma la caduta dei capelli č il pavimento!!!
Azz... hai ragione, ammetto la mia enorme lacuna in materia di
calvizie e mi rimetto all'inappellabile giudizio del NG. Frustatemi
senza pietą (pliz!). ;-))))


 wrote in message
news:958uiuokv1sinqe33...@4ax.com...


non si curano?
Ma la calvizie E` una malattia? 
-- 
paolo,
mailto: 
pde...@despammed.com
 -  pdeste [at] 
vene.dave.it
"Whenever you find yourself on the side of the majority, it's time to
pause and reflect" Mark Twain
---> *** Combatti lo SPAM: 
http://www.politik-digital.de/spam/
 ***

non si curano?
Intendi dire "Artrosi", vero? Sta di fatto che ai malati di artrosi si
somministrano cure palliative che non risolvono la patologia. In ogni
caso il paragone mi sembra quanto meno azzardato.
Ciao


 wrote in message
news:8mmviug05aoasb5sk...@4ax.com...

Perchč azzardato?Dal punto di vista biologico calvizie a artrite reumatoide
sono due malattie auto immuni in soggetti predisposti.
PS
Volevo dire artrite non artrosi


Volevo dire artrite non artrosi
Tu hai parlato di malattie degenerative a l'artrite č a eziologia
infiammatoria, mentre l'artrosi č degenerativa.
Ciao


 ha scritto nel messaggio
news:8d8c4aaf.02071...@posting.google.com...



Ecco l'uso del tacrolimus per la cura della Calvizie!!!
---------------------------------------------------------
I thought some of you may be interested in Tacrolimus abstracts.  The
bottom line is that Tacrolimus appears to be safe if used topically, grows
hair in experimental animals, and is more effectively absorbed through the
skin than cyclosporin.  It also seems to grow hair topically while causing
hair loss if taken orally.
Dr. P,
How can the same drug cause hair growth topically, and hair loss orally?
Bizarre?
Anyone having any success with this drug used topically in a 0.1%
concentration?  If so, what was your hair loss pattern, how long have you
been using Tacrolimus, and what type of results/side effects have your
experienced?
Bryan/mike/MaLeake,
I would love to have your interpretation of these abstracts and possibly
the full studies if you get the chance.
J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):637-44
A randomized, vehicle-controlled trial of tacrolimus ointment for treatment
of atopic dermatitis in children. Pediatric Tacrolimus Study Group.
Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM
National Jewish Medical and Research Center and the Department of
Pediatrics, University of Colorado Health Sciences Center, Denver, USA.
BACKGROUND: A topical formulation of tacrolimus, an immunosuppressant
currently marketed for the prevention of rejection after solid organ
transplant, is a potential therapeutic agent for atopic dermatitis.
OBJECTIVE: We sought to determine the safety and efficacy of tacrolimus
ointment in pediatric patients with moderate-to-severe atopic dermatitis.
METHODS: In this double-blind, vehicle-controlled multicenter trial,
children ages 7 to 16 years were treated with twice daily application of
tacrolimus ointment at 1 of 3 concentrations (0.03% [n = 43], 0.1% [n =
49], or 0.3% [n = 44]) or vehicle (n = 44) for up to 22 days, with a 2-week
follow-up period. RESULTS: The Physician's Global Evaluation of clinical
response showed that 69% (95% confidence interval: 53-82) of patients in
the 0.03% tacrolimus ointment group, 67% (95% confidence interval: 52-81)
in the 0.1% tacrolimus ointment group, and 70% (95% confidence interval:
54-83) in the 0.3% tacrolimus ointment group, compared with 38% (95%
confidence interval: 24-54) in the vehicle group, had a marked to excellent
(> or =75%) improvement or clearing of their atopic dermatitis (P =.005,
.007, and .004, respectively for the 3 tacrolimus groups compared with the
vehicle group). The mean percent improvement for a modified Eczema Area and
Severity Index at end of treatment for each of the 3 tacrolimus groups
(0.03%, 72%; 0.1%, 77%: and 0.3%, 81%) was significantly better than that
of the vehicle group (26%; P <.001). The median percent reduction in
pruritus was significantly greater for tacrolimus-treated patients (74%
 to 89%) than for vehicle-treated patients (51%, P = .027). No serious
systemic adverse events were noted, and systemic absorption was minimal.
CONCLUSION: Tacrolimus ointment appears to be safe and effective in
children with atopic dermatitis.
Publication Types:
     Clinical trial
     Multicenter study
     Randomized controlled trial
Comments:
     Comment in: J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):555-7
PMID: 9802373, UI: 99017359
Absorption of topical tacrolimus (FK506) in vitro through human skin:
comparison with cyclosporin A.
Lauerma AI, Surber C, Maibach HI
Department of Dermatology, University of California, School of Medicine,
San Francisco, USA.
Cyclosporin A (CsA) is efficacious in many dermatoses as an oral but not
asa topical form, while tacrolimus (FK506) has been shown to be effective
in both forms. As inadequate skin absorption has been proposed as the
reason for inefficacy
of topical CsA, factors contributing to percutaneous absorption of FK506
and CsA were studied. Partitioning of FK506 and CsA between octanol and
water, stratum corneum and water, and stratum corneum and isopropyl
myristate was
determined. Absorption of FK506 and CsA through dermatomed human cadaver
skin was determined with in vitro flow-through cells. In partitioning
experiments, CsA was more lipophilic than FK506. Both drugs were seen in
comparable amounts in skin
layers, but FK506 permeated the skin to a greater extent than CsA.
PMID: 9449161, UI: 98110741
Topical FK506: a potent immunotherapy for alopecia areata? Studies using
the Dundee experimental bald rat model.
McElwee KJ, Rushton DH, Trachy R, Oliver RF
Department of Biological Sciences, University of Dundee, U.K.
We elected to examine the efficacy of the topically applied
immunosuppressive agent FK506 (Prograf) in the treatment of alopecia areata
(AA) using the Dundee experimental bald rat (DEBR) model. Thirty lesional
DEBR rats were allocated to five groups of six. Group 1 rats received 0.1
mL of a 0.25% solution of FK506 within a 2 x 2 cm marked area on one bald
flank twice a week (125 micrograms FK506/cm2 per week) for 8 weeks, while
the contralateral flank was left untreated. In group
II, 0.05 mL of a 0.1% solution of FK 506 was applied 5 days per week on one
flank (62.5 micrograms FK506/ cm2 per week) and control vehicle to the
opposite flank for 8 weeks. Group III rats were treated as in group II
except that drug and vehicle were applied twice a week (25 micrograms
FK506/cm2 per week) for 4 weeks. A positive control group received orally
administered cyclosporin A (CsA) (10 mg/kg daily) for 8 weeks and a further
group was left untreated. Rats were regularly examined and photographed
with skin biopsies taken from groups II and III. All FK 506-treated rats
regrew hair at the site of drug application within 14-21 days. Growth
continued for 3 weeks beyond termination of treatment after which gradual
hair loss was observed. No hair growth was seen as a result of vehicle
application and hair loss continued on untreated areas and in the untreated
control group. Immunohistology revealed a drastic reduction in the
follicular inflammatory infiltrate at the site of the FK506 application.
The oral CsA group responded by simultaneous regrowth of hair over the
whole body. Our findings suggest that FK506 may have considerable potential
as a topical treatment for AA.
PMID: 9390322, UI: 98052024
Am J Pathol 1997 Apr;150(4):1433-41
Hair growth modulation by topical immunophilin ligands: induction of
anagen, inhibition of massive catagen development, and relative protection
from chemotherapy-induced alopecia.
Maurer M, Handjiski B, Paus R
Department of Dermatology, Charite Hospital, Humboldt-Universitat zu
Berlin, Germany.
Selected immunophilin ligands (IPLs) are not only potent immunosuppressants
but also modulate hair growth. Their considerable side effects, however,
justify at best topical applications of these drugs for the management of
clinical hair
growth disorders. Therefore, we have explored hair growth manipulation by
topical cyclosporin A (CsA) and FK 506 in previously established murine
models that mimic premature hair follicle regression (catagen) or
chemotherapy-induced
alopecia, two major pathomechanisms underlying human hair loss. We confirm
that topical CsA and FK 506 induce active hair growth (anagen) in the back
skin of C57BL/6 mice with all follicles in the resting stage (telogen) and
show that both IPLs also inhibit massive, dexamethasone-induced, premature
catagen development in these mice. Furthermore, we demonstrate that CsA and
FK 506 provide relative protection from alopecia and follicle dystrophy
induced by cyclophosphamide, possibly by favoring the dystrophic anagen
pathway of follicle response to chemical damage. Although it remains to be
established whether these IPLs exert the same effects on human hair
follicles, our study provides proof of the principle that topical IPLs can
act as potent manipulators of clinically relevant hair-cycling
pathomechanisms. This strongly encourages one to explore the use of topical
IPLs in the management of human hair growth disorders.
PMID: 9094998, UI: 97249093
J Dermatol Sci 1994 Jul;7 Suppl:S47-54
Hair growth-stimulating effects of cyclosporin A and FK506, potent
immunosuppressants.
Yamamoto S, Kato R
Department of Pharmacology, School of Medicine, Keio University, Tokyo,
Japan.
Cyclosporin A (CsA), a cyclic endecapeptide, is a T cell-specific
immunosuppressant and is successfully used in the field of organ
transplantation. Another T cell-specific immunosuppressant, FK506, a more
recently discovered macrolide antibiotic, is effective against graft
rejection at much lower doses than CsA. Although totally different in
structure, both compounds inhibit T cell activation by interfering with the
production of interleukin-2 (IL-2) by inhibiting IL-2 gene expression,
probably through the inhibition of calcineurin, a Ca2+/calmodulin-dependent
phosphatase. Clinical studies have revealed that FK506 induces a variety of
side effects in common with CsA. One of the most common side effects of CsA
is hypertrichosis. The hair growth stimulating effect of CsA is observed
not only in normal but also in pathological conditions of hair growth, i.e.
in patients with alopecia areata and also in some patients with
male-pattern alopecia. Although hypertrichosis is induced by both topical
and oral administration of CsA, there has been no report showing that FK506
induces hypertrichosis. Recently we have found that
topical application of FK506 to skins of mice, rats and hamsters markedly
stimulates hair growth. This hair growth stimulating effect of FK506 is
observed when applied topically but not by oral administration, even with a
dose which causes marked immunosuppression. The hair growth stimulating
effect of FK506 in normal animals may apparently be unrelated to its
immunosuppressive effect. In vitro studies revealed that FK506 directly
stimulates hair follicles. Mechanisms of hair growth
stimulating effects of FK506 and CsA remain to be elucidated.
Publication Types:
     Review
     Review, tutorial
PMID: 7528050, UI: 95092662
J Invest Dermatol 1994 Feb;102(2):160-4
Stimulation of hair growth by topical application of FK506, a potent
immunosuppressive agent.
Yamamoto S, Jiang H, Kato R
Department of Pharmacology, School of Medicine, Keio University, Tokyo,
Japan.
FK506, a macrolide antibiotic produced by Streptomyces tsukubaensis, is
known as a potent T cell-specific immunosuppressant, and is effective
against graft rejection after organ transplantation. Topical application of
FK506 (0.03-1 mumol) to dorsal skin of CD-1 mice stimulated hair growth in
a dose-dependent manner. Unlike topical application, oral administration of
30 mg/kg of FK506, a dose that induces marked immunosuppression, did not
stimulate significant hair growth.Topical application of FK506 also
stimulated hair growth of rats and Syrian golden hamsters. FK506 stimulated
hair growth even in SCID mice that lack both B- and T-cell immunity.
Therefore, it is unlikely that the hair growth-stimulatory effect of FK506
results from its immunosuppressive effect. FK506 (0.01-1 microM) stimulated
both [3H]thymidine and [3H]glycine uptakes to cultured mouse vibrissae
follicles in a concentration-dependent manner. Moreover, when the follicles
were
treated with FK506 (1 microM) for 16 d, the size of the follicles (length
of hair plus follicle) increased slightly but significantly. On the other
hand, the size of the non-treated follicles did not increase significantly.
These results indicate that FK506 directly stimulates hair follicles.
Long-term treatment of mice with FK506, i.e., topical application of 1
mumol FK506 twice a week for 6 months, did not affect body weight gain of
mice, and the FK506-treated mice looked healthy. FK506 may be useful as a
stimulant of hair growth.
PMID: 7508960, UI: 94149285
----------------------------------------------------------------------------
----

Ecco l'uso del tacrolimus per la cura della Calvizie!!!
Sì ma cacchio... personalmente se soffrissi di calvizie non mi
spingerei a tanto. Non utilzzerei la finasteride, figuriamoci il
tacrolimo!! C'è chi è costretto ad assumere gli immunosoppressori a
vita a causa di un trapianto e chi consiglia di utilizzarli per
banalità quali la calvizie. De gustibus...
